A clinical trial testing an IDO1 inhibitor in combination with a therapeutic melanoma vaccine failed to boost tumor-fighting T cells in advanced melanoma. Researchers led by Craig L. Slingluff at the University of Virginia evaluated whether blocking IDO1—an immunosuppressive pathway inside tumors—would amplify vaccine-driven immune responses. The result is scientifically informative even as it is clinically sobering: the combination did not produce the expected cellular activation and expansion signatures tied to stronger antitumor efficacy. Trials like this are often used to refine next-generation combinations by identifying which immunosuppressive targets are functionally relevant in specific tumor microenvironments. For developers, the key takeaway is the continued difficulty of translating vaccine priming into sustained effector T-cell gains, particularly when tumors deploy multiple non-redundant resistance mechanisms. The data may redirect resources toward alternative immune modulators or stratification strategies. (Selected item reflects the trial outcome rather than preclinical framing.)